Dr. Doreen Grech is the Founder and Principal of Tudor Life Science Advisors, a consultancy firm providing strategic and business development services to academic, nonprofit and biopharma clients. Prior to starting Tudor in 2017, Doreen was Director, External Partnerships for the Global Neurology Business Unit at UCB Pharma, a Belgium-based biopharmaceutical company. She held various business development roles during her tenure at UCB (2009-2016), including Director, CNS Scouting and Partnering, Business Development Lead, Global Clinical Development and Medical Organization, Director, US Business Development and Director, R&D Partnering and Business Development.
Prior to UCB, Doreen spent three years with a venture-backed, oncology-focused biopharma company and eight years in the venture capital industry working with early-stage life science companies and entrepreneurs. Doreen has expertise in assessing and developing life sciences technologies and products, building start-up companies, developing teams and managing growth.
Previous employers include Gloucester Pharmaceuticals (now Celgene) (2007-2009), RCT BioVentures (2005-2006), Pappas Ventures LLC (1998-2005) and Cato Research Ltd (1996-1998). Doreen received a BA in Biology from University of California, Santa Barbara, a MS in Biology from Texas A&M University and a PhD in Pharmacology & Toxicology from Medical College of Virginia, Virginia Commonwealth University.